Dr. Risa Stack has 15 years of experience investing in personalized medicine, therapeutics, and platform technologies. Her investment career spans incubations to public companies. Most recently she has focused starting companies, often taking operational roles.
Since joining Kleiner Perkins Caufield & Byers in 2003, Risa has worked to build and support KPCB's personalized medicine portfolio. She has been the founding CEO and a board member of several personalized medicine companies including Nodality and CardioDx. Risa is a board observer at Xdx, Veracyte, and Tethys. In addition to her work directly with portfolio, Risa is involved in developing public policy in molecular diagnostics and personalized medicine.
Risa is involved in the development of therapeutics companies including Trius and Corthera. She was most recently a board member of Corthera which was sold to Novartis in December 2009. She is also a board observer at Epizyme and Pacific Biosciences.
Prior to joining KPCB, Risa was a Principal at J.P. Morgan Partners in the life science practice for six years. While at J.P. Morgan Partners she sponsored a series of investments including Acurian, Connetics (acquired by Steifel Laboratories), Diatide (acquired by Berlex), Ilex Oncology (acquired by Genzyme), Illumina, and Triangle Pharmaceuticals (acquired by Gilead). Risa was also involved in JP Morgan Partners' international investing efforts, which included European life sciences companies and managing a portfolio of Israeli early stage life science and IT companies.
Before joining the venture capital industry, Risa worked as a Derivative Specialist on the Chicago Board of Trade where she traded futures and options on government securities.
Risa received her B.S. in Genetics and Development with distinction from the University of Illinois and her Ph.D. in Immunology from the University of Chicago. She was also a member of the second class of Kauffman Fellows.
Risa is a member of the advisory board of the National Summit on Personalized Healthcare and GE's Healthymagination effort.
Risa was named as one of the 100 Most Influential Women in Business by the San Francisco Business Times in 2004.
E-mail: risas@kpcb.com.
Since joining Kleiner Perkins Caufield & Byers in 2003, Risa has worked to build and support KPCB's personalized medicine portfolio. She has been the founding CEO and a board member of several personalized medicine companies including Nodality and CardioDx. Risa is a board observer at Xdx, Veracyte, and Tethys. In addition to her work directly with portfolio, Risa is involved in developing public policy in molecular diagnostics and personalized medicine.
Risa is involved in the development of therapeutics companies including Trius and Corthera. She was most recently a board member of Corthera which was sold to Novartis in December 2009. She is also a board observer at Epizyme and Pacific Biosciences.
Prior to joining KPCB, Risa was a Principal at J.P. Morgan Partners in the life science practice for six years. While at J.P. Morgan Partners she sponsored a series of investments including Acurian, Connetics (acquired by Steifel Laboratories), Diatide (acquired by Berlex), Ilex Oncology (acquired by Genzyme), Illumina, and Triangle Pharmaceuticals (acquired by Gilead). Risa was also involved in JP Morgan Partners' international investing efforts, which included European life sciences companies and managing a portfolio of Israeli early stage life science and IT companies.
Before joining the venture capital industry, Risa worked as a Derivative Specialist on the Chicago Board of Trade where she traded futures and options on government securities.
Risa received her B.S. in Genetics and Development with distinction from the University of Illinois and her Ph.D. in Immunology from the University of Chicago. She was also a member of the second class of Kauffman Fellows.
Risa is a member of the advisory board of the National Summit on Personalized Healthcare and GE's Healthymagination effort.
Risa was named as one of the 100 Most Influential Women in Business by the San Francisco Business Times in 2004.
E-mail: risas@kpcb.com.